| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1d3b6e03a92d64f0e4893a8b297f7647 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16322
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16334
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55544
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-88
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-21 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-88
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2001-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0aac50956622ca03e7604f172a4d145c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58a1b1ab73794d123ef0b10ecc85dbdf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba10bb5f23690b458a342a106a1e72a1 |
| publicationDate |
2002-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2421409-A1 |
| titleOfInvention |
Use of lipopeptides for immunotherapy of hiv-positive subjects |
| abstract |
The subject of the present invention is the use of lipopeptides for the preparation of a vaccine to control viral rebound in subjects HIV + on anti-retroviral therapy with a lower viral load or equal to 10,000 copies per ml of plasma and a CD4 + level greater than or equal to 300 cells per mm3, in which the lipopeptides consist of a peptide chain of 7 to 100 amino acids comprising at least one CTL epitope of an HIV protein, covalently linked to a lipid chain comprising from 8 to 20 carbon atoms. |
| priorityDate |
2000-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |